We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Bacterial BarCodes and Agilent in Marketing Agreement

By HospiMedica staff writers
Posted on 17 Oct 2003
A reseller agreement has been announced by Agilent Technologies, Inc. More...
(Palo Alto, CA, USA) and Bacterial BarCodes (Houston, TX, USA) under which Bacterial BarCodes will market the Agilent 2100 bioanalyzer as a key component of a new system called DiversiLab System.

The DiversiLab System will enable users in clinical epidemiology, food safety, and pharmaceutical research to rapidly track the source and spread of a bacterial infection or contamination. Bacterial BarCodes has developed a repetitive sequence-based polymerase chain reaction (rep-PCR)-based DNA fingerprinting technology that will be combined with the Agilent 2100 bioanalyzer and the LabChip and reagents of Caliper Technologies (Hopkinton, MA, USA) to create the DiversiLab System. The Agilent 2100 is a microfluidics-based system for analyzing RNA, DNA, proteins, and cell fluorescence. It performs automated quality control, sizing, and quantification of nucleic acids or proteins, and simple flow cytometric analyses, all on one platform.

"The Agilent 2100 bioanalyzer provides our DiversiLab System with a standardized, automated platform for sample analysis, enabling our customers to quickly and effectively respond to a microbial outbreak,” noted David McWilliams, CEO of Bacterial BarCodes.





Related Links:
Agilent Technologies
Bacterial BarCodes

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Total Thyroxine Assay
Total Thyroxine CLIA Kit
New
Luteinizing Hormone Assay
DRG LH-Serum ELISA Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.